The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review.

Abstract

With the increasing clinical potential of tumor immunotherapy, more and more clinical trials are undergoing with immune checkpoint inhibitors (ICIs). Immune checkpoints (ICs) have been identified as crucial regulators of the immune response and have improved ICIs-inhibitor therapeutic strategies. The most important ICs in lung cancer include programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), lymphocyte activation gene-3 (LAG-3), major histocompatibility complex class II (MHC II), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), and Galectin-9 (GAL-9), OX-40, OX40L. However, the expression and prognostic value of these ICs are still controversial. Among them, high expression of PD-L1 on tumor cells (>50%) predicts a better therapeutic effect of anti-PD-1 monoclonal antibody compared to patients with low PD-L1 expression. However, only 20-30% of non-small cell lung cancer (NSCLC) patients seem to get benefit from immunotherapy. In order to improve the immunotherapy outcomes, more and more attention is paid to combination immunotherapy. Analyzing the co-expression of ICs can give us a more comprehensive basis for combination immunotherapy. This review article summarized our comprehensive expression of ICs based on our previous research, and analyzed their correlation with prognosis in NSCLC patients. We also provided suggestions for potentially personalized combination immunotherapy in NSCLC.

• Authors: Yu Liu, Peixin Chen, Hao Wang, Shengyu Wu, Sha Zhao, Yayi He, Caicun Zhou, Fred R Hirsch
• Journal: Translational lung cancer research (Transl Lung Cancer Res) Vol. 10 Issue 2 Pg. 1029-1038 (Feb 2021) ISSN: 2218-6751 [Print] China
• PMID: 33718041 (Publication Type: Journal Article, Review)
• Copyright: 2021 Translational Lung Cancer Research. All rights reserved.